From cancer immunosurveillance to cancer immunotherapy (Q36990588)

17 August 2017

1 reference

title

From cancer immunosurveillance to cancer immunotherapy (English)

1 reference

17 August 2017

1 reference

Ricky W Johnstone

0 references

Mark J Smyth

0 references

John Stagg

1 reference

17 August 2017

language of work or name

1 reference

1 December 2007

1 reference

17 August 2017

published in

Immunological Reviews

1 reference

17 August 2017

volume

220

1 reference

17 August 2017

page(s)

82-101

1 reference

17 August 2017

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Apoptosis: a link between cancer genetics and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Immune surveillance of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Cancer despite immunosurveillance: immunoselection and immunosubversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Restoration of p53 function leads to tumour regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Modeling the therapeutic efficacy of p53 restoration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The DNA damage response arouses the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The serial cultivation of human diploid cell strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

A DNA damage checkpoint response in telomere-initiated senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

DNA repair, genome stability, and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Oncogene-Induced Senescence: Putting the Brakes on Tumor Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Senescence as an anticancer mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Oncogene-induced senescence pathways weave an intricate tapestry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Microarray analysis of replicative senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Tumour-educated macrophages promote tumour progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The Bcl-2 apoptotic switch in cancer development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

When cells die II: a comprehensive evaluation of apoptosis and programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

TRAIL resistance results in cancer progression: a TRAIL to perdition?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Clearance of apoptotic cells: getting rid of the corpses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Immune tolerance after delivery of dying cells to dendritic cells in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Innate immune recognition of viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Molecular identification of a danger signal that alerts the immune system to dying cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Gout-associated uric acid crystals activate the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Toll-like receptors in systemic autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

NKG2D and cytotoxic effector function in tumor immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

NKG2D function protects the host from tumor initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Transforming growth factor-beta regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Balancing co-stimulation and inhibition with BTLA and HVEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The new B7s: playing a pivotal role in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

B7-H3 promotes acute and chronic allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Cbl: many adaptations to regulate protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

A2A adenosine receptor protects tumors from antitumor T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

TGF-beta: a mobile purveyor of immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Type 1 T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Natural regulatory T cells: mechanisms of suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Toward an understanding of NKT cell biology: progress and paradoxes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Functional plasticity of macrophages: reversible adaptation to changing microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

IL-23 promotes tumour incidence and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Development of TLR9 agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Targeting death-inducing receptors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Bortezomib: proteasome inhibition as an effective anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

HDACs and the senescent phenotype of WI-38 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The role of histone acetylation versus DNA damage in drug-induced senescence and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Natural adjuvants: endogenous activators of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Eradication of established tumors in mice by a combination antibody-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Triggering CD40 on endothelial cells contributes to tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Targeting the TGF beta signaling network in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Transforming growth factor-beta in T-cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Inhibition of TGFbeta signaling in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Development of TGF-beta signalling inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Interleukin-10 in viral diseases and cancer: exiting the labyrinth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Selective Inhibition of I B Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Dendritic Cell-Based Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2007.00566.X

10.1111/J.1600-065X.2007.00566.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference